Gern (Geron Corp)

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
megab
Forum gebruiker
Forum gebruiker
Berichten: 191
Lid geworden op: 24 Aug 2018 19:02
waarderingen: 58
Contact:

Re: Gern (Geron Corp)

Berichtdoor megab » 13 Jun 2019 23:56

Mijn aandelen zijn niet meer uitgeleend en dan deze plotse stijging... Iemand een idee of is dit weer gewoon een tijdelijke speelbal tot er nieuws komt? :roll:



powered by Surfing Waves

Gebruikersavatar
Naz-T
Forum actieveling
Forum actieveling
Berichten: 632
Lid geworden op: 06 Sep 2018 20:48
waarderingen: 236
Contact:

Re: Gern (Geron Corp)

Berichtdoor Naz-T » 14 Jun 2019 06:18

megab schreef:Mijn aandelen zijn niet meer uitgeleend en dan deze plotse stijging... Iemand een idee of is dit weer gewoon een tijdelijke speelbal tot er nieuws komt? :roll:

Staan weer paar events gepland deze maand. Misschien stijging in aanloop daartoe en dan afhankelijk van wat er gezegd wordt een verdere stijging of terug daling. Altijd hetzelfde liedje. Bij mij liggen ze op de plank en hopelijk zien we de 4 ooit nog eens. Wat de koers ondertussen doet, lig ik niet van wakker.

vlere
Forum gebruiker
Forum gebruiker
Berichten: 181
Lid geworden op: 06 Mar 2017 16:04
waarderingen: 45
Contact:

Re: Gern (Geron Corp)

Berichtdoor vlere » 14 Jun 2019 06:20

megab schreef:Mijn aandelen zijn niet meer uitgeleend en dan deze plotse stijging... Iemand een idee of is dit weer gewoon een tijdelijke speelbal tot er nieuws komt? :roll:


Amai jij moet er veel hebben :D
Morgen is er een presentatie afwachten wat dat wordt. Ik hoop dat we dezelfde weg kunnen opgaan zoals vorig jaar!!!
Zou het wel kunnen gebruiken want port staat serieus in MIN :|

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 269
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 109
Contact:

Re: Gern (Geron Corp)

Berichtdoor And its gone! » 15 Jun 2019 22:34

Zag dat Gern trending is vandaag op Yahoo finance, op een zaterdag...
Zou maandag mogelijk een interessant dagje kunnen worden, of niet natuurlijk ;)
ancaoli liked last!

ancaoli
Forum actieveling
Forum actieveling
Berichten: 948
Lid geworden op: 28 Jan 2018 18:54
waarderingen: 482
Contact:

Re: Gern (Geron Corp)

Berichtdoor ancaoli » 16 Jun 2019 10:28

Imetelstat Provides Durable Transfusion Independence in Lower-Risk Relapsed/Refractory MDS
Virginia Powers, PhD
Published: Friday, Jun 14, 2019

Pierre Fenaux MD, PhD
Pierre Fenaux MD, PhD

Imetelstat treatment may allow patients with debilitating anemia due to myelodysplastic syndrome (MDS) to remain transfusion-free for extended periods of time, according to updated data from the phase II/III IMerge trial.1

Results presented at the 2019 European Hematology Association (EHA) Congress showed that treatment with single-agent imetelstat yielded an 8-week transfusion independence (TI) rate of 42% in heavily transfusion-dependent patients with MDS. These responses were durable, with patients showing a median duration of response (DoR) of 85.9 weeks (range, 8.0-140.9). Twenty nine percent of patients achieved 24-week TI. Furthermore, the mean relative reduction in red blood cell transfusion from baseline was 68%.

“Imetelstat is a first-in-class telomerase inhibitor that targets cells with short telomere length and active telomerase,” explained Pierre Fenaux MD, PhD, chairman of Groupe Francophone des Myélodysplasies, head of one of the hematology sections at Hôpital Saint Louis, and professor of hematology at Paris University.

Higher telomerase activity and shorter telomeres in the blood cells of some patients with lower-risk MDS are known to predict for shorter overall survival. Previously reported data have demonstrated clinical benefit with imetelstat in this patient population;2 the agent has also been shown to have clinical activity in myelofibrosis.3

In the open-label, single-arm trial, investigators evaluated the efficacy of imetelstat in patients with lower-risk MDS. Specifically, the trial enrolled patients with low-risk, non-del(5q) MDS, who were relapsed or refractory to erythropoietin stimulating agents (ESAs) and had not been previously treated with lenalidomide or hypomethylating agents, which are not authorized in Europe for this indication.

The patients had a heavy transfusion requirement; 92% of patients (n = 35) had a baseline transfusion burden of more than 4 units every 8 weeks; the median transfusion burden was 8 units every 8 weeks (range, 4-14 units). The International Prognostic Scoring System (IPSS), which is based upon the percentage of leukemic blast cells in the marrow, the type of chromosomal changes in the marrow cells, and the presence of cytopenia was intermediate-1 (0.5-1) in 37% of patients (n = 14). Additionally, 71% of patients (n = 27) had WHO 2001 RARS or RCMD-RS subtype, and 32% of patients (n = 12) had baseline serum EPO levels >500 mU/mL. The patients were mostly men (66%; n = 25) with a median age of 71.5 years (range, 46-83 years). Prior EPO use was reported for 89% of patients (n = 34).

Imetelstat was administered intravenously at 7.5 mg/kg every 4 weeks for a median of 9 cycles to 13 patients in the initial cohort and 25 patients in the expansion cohort. The 8-week TI rate served as the primary endpoint of the trial, while the key secondary endpoints included 24-week TI rate, safety, duration of TI, and the hematologic improvement (HI) rate, which was defined as transfusion reduction of at least 4 units every 8 weeks.

Overall, median follow-up was 12.1 months for the 38 patients; however, follow-up was 30.4 months in the initial cohort and 11.6 months in the expansion cohort.

Five (13%) patients achieved a complete response (CR) with 4 (10%) patients showing a CR in the marrow; this translated to an overall CR rate (CR + marrow CR) of 24% (n = 9). No partial responses were observed.

The presence of ring sideroblasts or baseline serum erythropoietin levels did not affect the 8-week TI rate.

Erythroid hematological improvements were seen in the majority of patients (68%; n = 26) as early as 8 weeks into treatment, and 32% of patients (n = 12) experienced an increase in hemoglobin of 1.5 gr/dL that lasted for 8 weeks or more.

Moreover, of the 16 patients who achieved 8-week TI, a high rise from baseline of 3g/dL was observed in 75% of patients (n = 12).

In a subgroup of 6 patients with IPSS-R intermediate or poor cytogenetic risk, all patients achieved 8-week TI, while 2 patients showed partial cytogenetic response.

The most frequently reported adverse events were determined to be manageable and reversible, including grade ≥3 cytopenia. No liver toxicity was observed.

“Single agent imetelstat provided meaningful and durable transfusion independence in patients with a high red blood cell transfusion burden and non-del(5q) lower-risk MDS who were relapsed or refractory to ESA,” Dr. Feneaux said.

“Transfusion independence was observed across different clinical subgroups, including patients with intermediate and poor cytogenetic risk; in fact, patients with a poorer prognosis showed better response, suggesting that the drug could translate to treatment of higher risk MDS patients,” he added. “These findings support part 2 of IMerge. We also plan to evaluate imetelstat in patients with higher-risk MDS.”
And its gone! liked last!
Vaste Portefeuille:Gala, Exmar, WRN, Accentis, Global G, SocGen, Roularta, Biocartis, Argenx, Enwave, Agfa, Accsys,Pure Gold Mining, Oxurion

vlere
Forum gebruiker
Forum gebruiker
Berichten: 181
Lid geworden op: 06 Mar 2017 16:04
waarderingen: 45
Contact:

Re: Gern (Geron Corp)

Berichtdoor vlere » 28 Jun 2019 20:23

Geron price target raised to $4.50 from $3.25 at B. Riley FBR B. Riley FBR analyst George Zavoico raised his price target for Geron to $4.50 from $3.25 after the company recently presented new results from its two trials of imetelstat in two different blood cancers. The results provide "strong evidence" of safety and efficacy that is "markedly superior" to current standard of care, Zavoico tells investors in a research note. He keeps a Buy rating on Geron.

Read more at:
https://thefly.com/landingPageNews.php?id=2927818

Alle de stijging mag dan eens beginnen!!


https://www.streetinsider.com/dr/news.php?id=15657571

megab
Forum gebruiker
Forum gebruiker
Berichten: 191
Lid geworden op: 24 Aug 2018 19:02
waarderingen: 58
Contact:

Re: Gern (Geron Corp)

Berichtdoor megab » 29 Jun 2019 15:15

Imetelstat, a Novel Drug with Unique Target
• Proprietary drug targeting telomerase-driven, uncontrolled progenitor cell proliferation in hematologic malignancies
• Development currently focused on two indications; both have significant unmet medical need and market opportunity
• Issued patent coverage until 2033 and orphan drug designation for MDS and MF

In-House Leadership and Expertise Establishes a Foundation for Potential Future Growth
• Highly-experienced in-house hematology-oncology and late-stage drug development team
Phase 3 Clinical Trial Starting August 2019 in Lower Risk Myelodysplastic Syndromes (MDS)
• Recently reported imetelstat Phase 2 efficacy data (8-week RBC-TI) compares favorably to data from the Phase 3 MEDALIST trial of luspatercept in high transfusion burden, lower risk MDS patients
• Randomized, placebo-controlled Phase 3 clinical trial planned to open for screening and enrollment in August 2019
• Fast Track designation granted

Preparing for End of Phase 2 Meeting for Relapsed/Refractory Myelofibrosis (MF)
• Recently reported statistical analyses suggest favorable overall survival for imetelstat-treated relapsed/refractory MF patients compared to
best available therapy (BAT) in closely matched patients from real-world data
End of Phase 2 meeting with FDA to potentially determine regulatory strategy for relapsed/refractory MF is planned by the end of Q1 2020

Complete Transition of Imetelstat Development Program
❑ Transfer IND sponsorship by the end of the second quarter
❑ Actively recruit hematology-oncology research and development expertise throughout 2019
❑ Chief Medical Officer
❑ Senior Leadership in Pharmacovigilance and Safety, Clinical Sciences/Operations, Clinical
Development, Biostatistics, Quality, Manufacturing
❑ Senior Leadership in Regulatory Affairs
MDS Development
❑ Updated data from the Phase 2 portion of IMerge presented at EHA in June 2019
❑ Site initiation for Phase 3 portion of IMerge in July 2019
❑ Commence screening and enrollment for Phase 3 portion of IMerge in August 2019
Prepare for End of Phase 2 Meeting with the FDA for Relapsed/Refractory MF
❑ Initiate discussions with MF KOLs
❑ Prepare analyses and regulatory strategies for End of Phase 2 meeting with the FDA in the
second half of 2019
❑ Schedule an End of Phase 2 meeting in the first quarter of 2020

Het kan nog interessant worden later dit jaar :)
And its gone! liked last!

strever
Forum actieveling
Forum actieveling
Berichten: 562
Lid geworden op: 04 Jan 2015 14:33
waarderingen: 193
Contact:

Re: Gern (Geron Corp)

Berichtdoor strever » 05 Jul 2019 17:31

Laatste dagen is er wel meer volume dan voordien!
Is natuurlijk niet vergelijkbaar met vorig jaar dat er dagelijks zo'n 60 miljoen over de toonbank ging.
Iets dat zijn kans gemist heeft krijgt zelden nog een tweede zit imo
!!!!Ben ik nu zo slim of is een ander zo dom?

koenvhaver
Forum actieveling
Forum actieveling
Berichten: 460
Lid geworden op: 11 Jan 2012 16:40
waarderingen: 98

Re: Gern (Geron Corp)

Berichtdoor koenvhaver » 15 Jul 2019 16:01

Blijft licht dalen. Nu al onder de 1.30. Komende maanden zullen niet veel nieuws brengen dus kan nog lager.
Return van 150% sinds 2016

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 269
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 109
Contact:

Re: Gern (Geron Corp)

Berichtdoor And its gone! » 15 Jul 2019 16:25

Bagholders. Dat zijn we! :lol:


Tijdelijke promo tot 31 augustus:






Reageren en meer functies krijgen?

Discussieer met duizenden beleggers, minder advertenties, ideaal voor smartphone, betere gebruikservaring en gratis abonneren op favoriete onderwerpen.

Registreer binnen enkele tellen